Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

Bella Kaufman(NYU Langone Health), Alison Jones(Roche (Switzerland)), A. Feyereislova(Roche (Switzerland)), John R. Mackey(University of Alberta), Cédric Révil(Roche (Switzerland)), Michaela Lehle(Roche (Switzerland)), Andrew Wardley(UK Research and Innovation), P. P. Bapsy, Michael Clemens(Klinikum Mutterhaus der Borromäerinnen), Sergei Tjulandin, Ashok K. Vaid(Medanta The Medicity), Michaela K. Jahn(Roche (Switzerland))
Journal of Clinical Oncology
September 29, 2009
10.1200/jco.2008.20.6847
Cited by 850

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
|Nature|2012|2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k